Sensus Healthcare, Inc. (FRA:5TX)
Germany · Delayed Price · Currency is EUR | Market Cap | 43.88M -39.9% |
| Revenue (ttm) | 19.54M -42.9% |
| Net Income | -6.74M |
| EPS | -0.41 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.540 |
| Previous Close | 2.640 |
| Day's Range | 2.540 - 2.540 |
| 52-Week Range | 2.300 - 4.760 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Sensus Healthcare
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 V... [Read more]
News
Sensus Healthcare management to meet virtually with Lake Street
Virtual Meeting to be held on June 18 hosted by Lake Street.
Sensus Healthcare management to meet virtually with Lake Street
Virtual Meeting to be held on May 21 hosted by Lake Street.
Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, tod...
Sensus Healthcare price target lowered to $6.50 from $7.50 at Alliance Global
Alliance Global lowered the firm’s price target on Sensus Healthcare (SRTS) to $6.50 from $7.50 and keeps a Buy rating on the shares, citing lower forecasts following the company’s Q1…
Sensus Healthcare reports Q1 EPS (16c), consensus (11c)
Reports Q1 revenue $3.4M, consensus $5.32M. “During the first quarter, we began our efforts in educating and training our existing customer base as well as our many new prospects. We…
Sensus Healthcare Earnings Call Transcript: Q1 2026
Revenue declined year-over-year due to loss of a major customer, but underlying growth was seen from a diversified base. New CPT codes and software initiatives are driving increased adoption, recurring revenue, and a positive outlook for sequential quarterly improvement in 2026.
Sensus Healthcare Earnings release: Q1 2026
Sensus Healthcare released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Sensus Healthcare Quarterly report: Q1 2026
Sensus Healthcare has published its Q1 2026 quarterly earnings report on May 7, 2026.
Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological...
Sensus Healthcare Proxy statement: Proxy filing
Sensus Healthcare filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological...
Sensus Healthcare files lawsuit against SkinCure for breach of contract
Sensus Healthcare (SRTS) announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology alleging breach…
Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare initiated with a Buy at Alliance Global
Alliance Global analyst Scott Henry initiated coverage of Sensus Healthcare (SRTS) with a Buy rating and $7.50 price target Sensus sells the SRT-100/Vision medical device to deliver superficial radiat...
Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare price target lowered to $6 from $8 at Maxim
Maxim analyst Anthony Vendetti lowered the firm’s price target on Sensus Healthcare (SRTS) to $6 from $8 and keeps a Buy rating on the shares. The company’s Q4 results were…
Sensus Healthcare reports Q4 EPS (19c) vs. 9c last year
Reports Q4 revenue $4.9M vs. $13.1M. “Following the publication of Current Procedural Terminology (CPT) codes for treating non-melanoma skin cancer with SRT in November – with a per-fraction increase ...
Sensus Healthcare Earnings Call Transcript: Q4 2025
Exclusive CPT codes for SRT and IG-SRT provide reimbursement clarity, supporting broader adoption and international growth. 2025 saw lower revenues and a net loss, but a strong balance sheet and diversified customer base position the company for profitability in 2026.
Sensus Healthcare Annual report: Q4 2025
Sensus Healthcare has published its Q4 2025 annual report on February 12, 2026.
Sensus Healthcare Earnings release: Q4 2025
Sensus Healthcare released its Q4 2025 earnings on February 12, 2026, summarizing the period's financial results.
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective trea...
Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...